Hebert Kathy, McKinnie James, Horswell Ron, Arcement Lee, Stevenson Lynne
Leonard J. Chabert Medical Center, Houma, Louisiana 70363, USA.
J Card Fail. 2006 Dec;12(9):689-93. doi: 10.1016/j.cardfail.2006.08.214.
Research regarding the use of implantable devices in patients with congestive heart failure (CHF) has shown mortality benefits. The Center for Medicare and Medicaid Services (CMS) approved new criteria for expanding coverage for such therapies. The purpose of this study was to determine the percentages of CHF patients in a rural, indigent heart failure population that would be eligible for implantable defibrillators (ICD) and cardiac resynchronization therapy (CRT) based on the new CMS criteria.
The new CMS guidelines were applied to information compiled in a database for 451 CHF disease management patients, at Leonard J. Chabert Medical Center. Results show that, annually, 32% of the newly identified CHF patient population would be eligible for ICD therapy and 7.3% would be eligible for CRT therapy.
Providers of health care to the indigent may lack sufficient resources for the devices and the infrastructure for device implantation and follow-up.
关于在充血性心力衰竭（CHF）患者中使用植入式设备的研究已显示出对死亡率的益处。医疗保险和医疗补助服务中心（CMS）批准了扩大此类治疗覆盖范围的新标准。本研究的目的是根据新的CMS标准，确定农村贫困心力衰竭人群中符合植入式心脏除颤器（ICD）和心脏再同步治疗（CRT）条件的CHF患者的百分比。
将新的CMS指南应用于伦纳德·J·查伯特医疗中心为451名CHF疾病管理患者编制的数据库中的信息。结果显示，每年新确诊的CHF患者群体中，32%符合ICD治疗条件，7.3%符合CRT治疗条件。
为贫困人口提供医疗服务的机构可能缺乏足够的资源来购置设备以及进行设备植入和后续跟进的基础设施。
